Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.62Last Year’s EPS
-1.19Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 10.42%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress towards submitting the BLA for INO-3107, resolution of manufacturing issues, publication of key data, and promising interim results for DMAb technology. However, financial challenges were noted with a decrease in cash and a reported net loss. Overall, the call presents a balanced outlook with important achievements countered by financial concerns.Company Guidance
During the Inovio First Quarter 2025 Financial Results Conference Call, the company provided detailed guidance on its key objectives and metrics. Inovio is on track to submit a Biologics License Application (BLA) for its lead candidate, INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), with the rolling submission set to begin in mid-2025 and completion by the end of the year. If approved for priority review, the Prescription Drug User Fee Act (PDUFA) date is anticipated by mid-2026. The company highlighted resolving a manufacturing issue and initiating device design verification testing, essential for the BLA submission. Clinical data showed that 72% of patients had a 50%-100% reduction in surgeries in the first year, increasing to 86% in the second year, with half of the patients needing no surgeries at all. Financially, Inovio reported a 20% decrease in operating expenses to $25.1 million for Q1 2025, compared to $31.5 million in Q1 2024, and ended the quarter with $68.4 million in cash, expecting the cash runway to extend into the first quarter of 2026.Progress Towards BLA Submission for INO-3107
Inovio remains on track to submit their BLA for INO-3107 for treating recurrent respiratory papillomatosis (RRP) with rolling submission in mid-2025 and completion by the end of the year. They aim for a PDUFA date in mid-2026 if priority review is granted.
Manufacturing Issue Resolved
The manufacturing issue involving the single-use array component of the CELLECTRA device has been resolved, and device design verification testing has begun.
Publication of Key Data
Clinical and immunology data from the Phase 1/2 trial of INO-3107 was published in Nature Communications in February.
Positive Interim Results for DMAb Technology
Promising interim results from a Phase 1 proof-of-concept trial evaluating DNA-Encoded Monoclonal Antibodies (DMAbs) were announced, showing sustained antibody production for COVID-19.
Market Opportunity and Commercial Readiness
Inovio's ongoing market research supports the potential of INO-3107 as the preferred product for RRP patients and physicians, with a significant market opportunity due to the lack of existing therapeutic options.
Reduction in Operating Expenses
Operating expenses decreased by 20% from $31.5 million in Q1 2024 to $25.1 million in Q1 2025.
Statistically Significant Reduction in Surgeries
In the first year, 72% of patients saw a 50% to 100% reduction in surgeries after starting treatment with INO-3107, increasing to 86% in the second year with half of the patients requiring no surgeries at all.
INO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $1.92 | $1.88 | -2.08% |
Mar 18, 2025 | $2.10 | $1.96 | -6.67% |
Nov 14, 2024 | $4.77 | $4.26 | -10.69% |
Aug 08, 2024 | $8.71 | $8.44 | -3.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inovio Pharmaceuticals (INO) report earnings?
Inovio Pharmaceuticals (INO) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Inovio Pharmaceuticals (INO) earnings time?
Inovio Pharmaceuticals (INO) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INO EPS forecast?
INO EPS forecast for the fiscal quarter 2025 (Q2) is -0.62.
